<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932669</url>
  </required_header>
  <id_info>
    <org_study_id>1811-074-985</org_study_id>
    <nct_id>NCT03932669</nct_id>
  </id_info>
  <brief_title>Effect of Nilotinib in Cerebellar Ataxia Patients</brief_title>
  <official_title>Effect of Nilotinib in Cerebellar Ataxia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an institutional cohort study. Patients confirmed with spinocerebellar ataxia (SCA)
      and taking or planning to take Nilotinib (TasignaÂ®) are enrolled in this study. The daily
      dose of Nilotinib is 150mg-300mg and the patients will be followed up at 1, 3, 6, and 12
      months. Rating scale for Friedreich's ataxia I and II and Barthel index are used as general
      function and daily living performance index. Scale for assessment and rating of ataxia (SARA)
      are used as an objective measure of cerebellar function. Adverse drug reactions are evaluated
      based on CTCAE version 4.0.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patients taking Nilotinib 1-1.Baseline information: demographics, genetic type of SCA,
           brain MRI, electrocardiography, routine blood evaluations 1-2. Time point of evaluation:
           At initiation of taking Nilotinib, 1, 3, 6, and 12 months 1-3. Evaluation items (at each
           time point) Routine check-up: electrocardiography, routine blood evaluations Adverse
           events: CTCAE version 4.0 Daily living performance: Barthel index General function:
           Friedreich's ataxia I and II 1-4. Change of drug dose Based on the attending physician's
           decision

        2. Patients planning to take Nilotinib 2-1.Baseline information: demographics, genetic type
           of SCA, brain MRI, electrocardiography, routine blood evaluations 2-2. Time point of
           evaluation: Baseline, 1, 3, 6, and 12 months 2-3. Evaluation items (at each time point)
           Routine check-up: electrocardiography, routine blood evaluations Adverse events: CTCAE
           version 4.0 Cerebellar function: Scale for assessment and rating of ataxia (SARA) Daily
           living performance: Barthel index General function: Friedreich's ataxia I and II 2-4.
           Change of drug dose Based on the attending physician's decision
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity of daily living</measure>
    <time_frame>12 month</time_frame>
    <description>Barthel index: score range 0-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebellar function</measure>
    <time_frame>12 month</time_frame>
    <description>Scale for the assessment and rating of ataxia (SARA): score range 0-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General function</measure>
    <time_frame>12 month</time_frame>
    <description>Rating scale for Friedreich's ataxia I: score range 0-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of daily living</measure>
    <time_frame>12 month</time_frame>
    <description>Rating scale for Friedreich's ataxia II: score range 0-36</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Baseline, 1 month, 3 month, 6 month, 12 month</time_frame>
    <description>CTCAE version 4.0</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ataxia, Cerebellar</condition>
  <arm_group>
    <arm_group_label>Nilotinib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with SCA and taking nilotinib treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>150-300mg daily dose of nilotinib</description>
    <arm_group_label>Nilotinib group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as chronic cerebellar ataxia

          -  Confirmed as spinocerebellar ataxia by gene test

        Exclusion Criteria:

          -  Laboratory abnormalities that could interfere with the proper use of Nilotinib QTc
             interval &gt;450ms on initial electrocardiograph, Hb &lt;8.0, WBC&lt;2000, ANC &lt;1600, PLT
             &lt;140,000, AST &gt;200, ALT&gt;200, ALP&gt;575, Positive HIV serology, active hepatitis B

          -  Unstable mental or physical status that could interfere with precise evaluation and
             proper management of SCA Heart failure (NYHA Grade III or IV), history of major heart
             disease Pregnancy, on breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kon Chu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee WJ, Moon J, Kim TJ, Jun JS, Lee HS, Ryu YJ, Lee ST, Jung KH, Park KI, Jung KY, Kim M, Lee SK, Chu K. The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia. J Neuroimmunol. 2017 Aug 15;309:82-87. doi: 10.1016/j.jneuroim.2017.05.015. Epub 2017 May 24.</citation>
    <PMID>28601294</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>spinocerebellar ataxia, treatment, nilotinib, bcr-abl inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The IPD will be provided upon request from any qualified investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

